4//SEC Filing
O'Brien Patrick 4
Accession 0001627183-26-000001
CIK 0000879407other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 9:50 PM ET
Size
34.6 KB
Accession
0001627183-26-000001
Insider Transaction Report
Form 4
Transactions
- Gift
Common Stock
2025-12-31−560→ 526,641 total - Gift
Common Stock
2025-12-31−560→ 526,081 total - Gift
Common Stock
2025-12-31−560→ 525,521 total - Gift
Common Stock
2025-12-31−560→ 524,961 total - Gift
Common Stock
2025-12-31−560→ 524,401 total - Sale
Common Stock
2026-01-05$61.20/sh−4,368$267,322→ 520,033 total - Sale
Common Stock
2026-01-05$62.23/sh−6,164$383,586→ 513,869 total - Sale
Common Stock
2026-01-05$62.96/sh−13,451$846,875→ 500,418 total - Sale
Common Stock
2026-01-05$63.84/sh−11,842$755,993→ 488,576 total - Sale
Common Stock
2026-01-05$64.44/sh−2,700$173,988→ 485,876 total - Sale
Common Stock
2026-01-05$66.01/sh−900$59,409→ 484,976 total - Sale
Common Stock
2026-01-05$68.00/sh−313$21,284→ 484,663 total - Sale
Common Stock
2026-01-05$61.12/sh−600$36,672→ 484,063 total - Sale
Common Stock
2026-01-05$62.25/sh−900$56,025→ 483,163 total - Sale
Common Stock
2026-01-05$62.91/sh−5,873$369,470→ 477,290 total - Sale
Common Stock
2026-01-05$64.04/sh−2,336$149,597→ 474,954 total - Sale
Common Stock
2026-01-05$68.00/sh−46$3,128→ 474,908 total
Footnotes (14)
- [F1]Gift to relatives
- [F10]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F11]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.75 to $61.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F12]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F13]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.54 to $63.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F14]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F2]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
- [F3]Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F4]Partial disposition of shares to satisfy tax withholding obligations.
- [F5]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F6]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F7]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F8]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.41 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F9]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Documents
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
CIK 0000879407
Entity typeother
Related Parties
1- filerCIK 0001627183
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 9:50 PM ET
- Size
- 34.6 KB